Sign in Subscribe
Class action lawsuits

MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Misleading Statements

Strategic Insights

— 1 min read

MoonLake Immunotherapeutics is facing a class action lawsuit after allegedly issuing false and misleading statements about its business, operations, and prospects, including its sole drug candidate, sonelokimab (SLK). The lawsuit claims that the company and its executives touted SLK's unique clinical advantages while failing to disclose that it targeted the same molecules as UCB's BIMZELX, which has superior efficacy. The suit was brought in the Southern District of New York and alleges that investors suffered significant losses due to the company's misrepresentations.

Key Takeaways:

  • The class action lawsuit was filed on behalf of an individual investor against MoonLake Immunotherapeutics and certain individuals, alleging violations of federal securities laws.
  • The suit claims that MoonLake misled investors about its sole drug candidate, sonelokimab (SLK), by touting its unique clinical advantages without disclosing that it targeted the same molecules as UCB's BIMZELX.
  • The lawsuit alleges that MoonLake's stock collapsed nearly 90% after the company announced Phase 3 results showing SLK's failure to match BIMZELX's efficacy.
  • The suit was brought in the Southern District of New York and was filed by Block & Leviton LLP, a law firm representing the individual investor.
  • The case is captioned Bridgewood v. MoonLake Immunotherapeutics et al., No. 1:25-cv-8500 (S.D.N.Y.).
  • The proposed class period includes all those who purchased or acquired MoonLake Immunotherapeutics common stock between March 10, 2024, and September 29, 2025.
  • Investors who purchased MoonLake Immunotherapeutics stock during the class period may be able to seek appointment as a lead plaintiff and must comply with the relevant provisions of the Private Securities Litigation Reform Act, 15 U.S.C. 78u-4.
  • The deadline for investors to move the Court for appointment as lead plaintiff is December 15, 2025.

Statistics:

  • MoonLake Immunotherapeutics' stock collapsed nearly 90% after announcing Phase 3 results showing SLK's failure to match BIMZELX's efficacy.
  • The class action lawsuit claims that investors suffered significant losses due to the company's misrepresentations.
  • The proposed class period includes investments from March 10, 2024, to September 29, 2025, both dates inclusive.

Sources:

  • GlobeNewswire, "MoonLake Immunotherapeutics Sued for $2 Trillion After Officers and Directors Announced Misleading Statements"
  • Block & Leviton LLP, "Class Action Lawsuit Against MoonLake Immunotherapeutics"
  • Private Securities Litigation Reform Act, 15 U.S.C. 78u-4

Read more